|
1
|
Kelley JR and Duggan JM: Gastric cancer
epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith MG, Hold GL, Tahara E and El-Omar
EM: Cellular and molecular aspects of gastric cancer. World J
Gastroenterol. 12:2979–2990. 2006.
|
|
3
|
Alberts SR, Cervantes A and van de Velde
CJ: Gastric cancer: epidemiology, pathology and treatment. Ann
Oncol. 14(Suppl 2): ii31–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fox JG and Wang TC: Inflammation, atrophy,
and gastric cancer. J Clin Invest. 117:60–69. 2007. View Article : Google Scholar
|
|
5
|
Li J, Ng EK, Ng YP, et al: Identification
of retinoic acid-regulated nuclear matrix-associated protein as a
novel regulator of gastric cancer. Br J Cancer. 101:691–698. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheung KF, Lam CN, Wu K, et al:
Characterization of the gene structure, functional significance,
and clinical application of RNF180, a novel gene in gastric cancer.
Cancer. 118:947–959. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu J, Cheng YY, Tao Q, et al: Methylation
of protocadherin 10, a novel tumor suppressor, is associated with
poor prognosis in patients with gastric cancer. Gastroenterology.
136:640–651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu WK, Lee CW, Cho CH, et al: MicroRNA
dysregulation in gastric cancer: a new player enters the game.
Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu WK, Cho CH, Lee CW, et al:
Dysregulation of cellular signaling in gastric cancer. Cancer Lett.
295:144–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrandina G, Mey V, Nannizzi S, et al:
Expression of nucleoside transporters, deoxycitidine kinase,
ribonucleotide reductase regulatory subunits, and gemcitabine
catabolic enzymes in primary ovarian cancer. Cancer Chemother
Pharmacol. 65:679–686. 2010. View Article : Google Scholar
|
|
11
|
Goan YG, Zhou B, Hu E, Mi S and Yen Y:
Overexpression of ribonucleotide reductase as a mechanism of
resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell
line. Cancer Res. 59:4204–4207. 1999.PubMed/NCBI
|
|
12
|
Engström Y, Eriksson S, Jildevik I, Skog
S, Thelander L and Tribukait B: Cell cycle-dependent expression of
mammalian ribonucleotide reductase. Differential regulation of the
two subunits. J Biol Chem. 260:9114–9116. 1985.PubMed/NCBI
|
|
13
|
Duxbury MS and Whang EE: RRM2 induces
NF-kappaB -dependent MMP-9 activation and enhances cellular
invasiveness. Biochem Biophys Res Commun. 354:190–196. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang K, Hu S, Wu J, et al: Overexpression
of RRM2 decreases thrombspondin-1 and increases VEGF production in
human cancer cells in vitro and in vivo: implication of RRM2 in
angiogenesis. Mol Cancer. 8:112009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zuckerman JE, Hsueh T, Koya RC, Davis ME
and Ribas A: siRNA knockdown of ribonucleotide reductase inhibits
melanoma cell line proliferation alone or synergistically with
temozolomide. J Invest Dermatol. 131:453–460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kang W, Tong JH, Chan AW, et al: Stathmin1
plays oncogenic role and is a target of microRNA-223 in gastric
cancer. PLoS One. 7:e339192012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang W, Tong JH, Chan AW, et al:
Yes-associated protein 1 exhibits oncogenic property in gastric
cancer and its nuclear accumulation associates with poor prognosis.
Clin Cancer Res. 7:2130–2139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou B and Yen Y: Characterization of the
human ribonucleotide reductase M2 subunit gene; genomic structure
and promoter analyses. Cytogenet Cell Genet. 95:52–59. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morikawa T, Hino R, Uozaki H, et al:
Expression of ribonucleotide reductase M2 subunit in gastric cancer
and effects of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kretschxmer C, Sterner-Kock A, Siedentopf
F, Schoenegg W, Schlag PM and Kemmner W: Identification of early
molecular markers for breast cancer. Mol Cancer. 10:152011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morikawa T, Maeda D, Kume H, Homma Y and
Fukayama M: Ribonucleotide reductase M2 subunit is a novel
diagnostic marker and a potential therapeutic target in bladder
cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Souglakos J, Boukovinas I, Taron M, et al:
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels
and clinical outcome of lung adenocarcinoma patients treated with
docetaxel/gemcitabine. Br J Cancer. 98:1710–1715. 2008. View Article : Google Scholar
|
|
23
|
Satow R, Shitashige M, Kanai Y, et al:
Combined functional genome survey of therapeutic targets for
hepatocellular carcinoma. Clin Cancer Res. 16:2518–2528. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Itoi T, Sofuni A, Fukushima N, et al:
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment
biopsies obtained from unresectable pancreatic carcinomas. J
Gastroenterol. 42:389–394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duxbury MS, Ito H, Benoit E, Zinner MJ,
Ashley SW and Whang EE: Retrovirally mediated RNA interference
targeting the M2 subunit of ribonucleotide reductase: a novel
therapeutic strategy in pancreatic cancer. Surgery. 136:261–269.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heidel JD, Liu JY, Yen Y, et al: Potent
siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce
cell proliferation in vitro and in vivo. Clin Cancer Res.
13:2207–2215. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou B, Liu X, Mo X, et al: The human
ribonucleotide reductase subunit hRRM2 complements p53R2 in
response to UV-induced DNA repair in cells with mutant p53. Cancer
Res. 63:6583–6594. 2003.PubMed/NCBI
|
|
28
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar
|
|
29
|
Hu ZZ, Huang H, Cheema A, Jung M,
Dritschilo A and Wu CH: Integrated bioinformatics for
radiation-induced pathway analysis from proteomics and microarray
data. J Proteomics Bioinform. 1:47–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang YW, Jones TL, Martin SE, Caplen NJ
and Pommier Y: Implication of checkpoint kinase-dependent
up-regulation of ribonucleotide reductase R2 in DNA damage
response. J Biol Chem. 284:18085–18095. 2009. View Article : Google Scholar : PubMed/NCBI
|
